Increased M2 macrophages are linked to EGFR-TKI resistance. Macrophage polarization (M2 to M1) may predict improved responses in EGFR-TKI-resistant NSCLC.Combining STING agonists or liposome therapies with EGFR TKIs reprograms TAMs, enhancing tumor regression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.